TrialCancer immunology, immunotherapy : CII2022

First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience.

Stefanie Kreutmair et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.